Specialty Pharmacy at a Crossroads: Navigating Access, Complexity, and Sustainability

This article explores how specialty pharmacies function today, where access most often breaks down, and why operational strategy has become inseparable from patient care.

Specialty pharmacies operate at the intersection of clinical complexity and financial risk. Unlike traditional retail pharmacies, they manage advanced therapies for chronic, rare, and difficult-to-treat conditions. These medications demand specialized handling, intensive clinical oversight, and deep familiarity with not only insurance and regulatory policy, but also complex workflows that can directly affect therapy timing.

Specialty drugs represent a growing share of total drug spending, and specialty pharmacies have more opportunities than ever before to expand patient care and business growth. At the same time, the environment around them is shifting quickly. Biosimilars are entering the market at an accelerating pace, federal programs such as 340B are being reinterpreted, and payor and pharmacy benefit manager (PBM) contracting continues to grow more complex and restrictive, To add to this, more drugs are shifting to the medical benefit, putting a strain on traditional billing systems that weren’t designed to handle the complexity of medical billing.

Together, these pressures are testing traditional specialty pharmacy models. Providing specialty medications now depends as much on operational and reimbursement expertise as it does on clinical excellence. From benefits investigation and prior authorization to claims processing and denial management, insurance navigation increasingly determines how quickly patients can start therapy and whether specialty pharmacies can remain financially viable.

Understanding Specialty Medications and Specialty Pharmacy Workflow

There is no single regulatory definition of a specialty medication, but the industry broadly agrees it is a therapy that is more complex and costly than a traditional prescription. Specialty medications typically require enhanced clinical oversight, individualized patient support, and specialized handling beyond standard retail pharmacy workflows.

Specialty medications commonly possess one or more of the following characteristics:

• Special storage or distribution requirements
• Limited or restricted access channels
• Personalized dosing, administration support, and ongoing monitoring
• High cost relative to standard prescriptions

Specialty therapies are used to treat conditions such as cancer, autoimmune and inflammatory diseases, genetic and metabolic disorders, infectious diseases, and fertility or hormonal conditions.

While many specialty drugs are biologics, others are chemically synthesized therapies classified as specialty due to cost, monitoring requirements, or restricted distribution. Because of their clinical and financial impact, payors rely heavily on utilization management tools such as formularies, prior authorization, step therapy, and PBM-specific policies to control access.

Biosimilars: Clinical Parity, Uneven Access

Despite their clinical equivalence to reference biologics being well-established, adoption of biosimilars remains inconsistent, and they have not yet had a meaningful impact on specialty drug costs.

In many cases, payors continue to favor higher-cost biologics due to rebate structures, legacy contracts, or vertically integrated PBM and specialty pharmacy arrangements. As a result:

• Lower-cost alternatives may be excluded from formularies
• Interchangeability status is underutilized
• Contract economics can outweigh clinical value

For patients, this often means delays or unexpected coverage barriers. For specialty pharmacies, it creates uncertainty in inventory planning, reimbursement expectations, and financial forecasting.

The Evolving Role of Specialty Pharmacies

Specialty pharmacies do far more than dispense medication. They serve as care coordinators, patient advocates, and reimbursement navigators, connecting providers, payors, manufacturers, and patients to keep therapy moving forward.

Core responsibilities include:

• Facilitating prior authorizations and benefits investigations
• Managing formulary and step-therapy restrictions
• Coordinating storage, shipping, and cold-chain logistics
• Supporting adherence through education and outreach
• Connecting patients to affordability and assistance programs

Operational models vary widely. Health-system specialty pharmacies often integrate services directly into care settings, while centralized or mail-order pharmacies focus on home delivery and remote monitoring. Payor- and PBM-owned pharmacies may streamline access within their networks, while independent pharmacies often differentiate through high-touch, personalized support.

Accreditation has also become a critical differentiator. While not legally required, many payors now expect specialty-specific accreditations, such as oncology or rare disease, as a condition of network participation. These requirements reinforce quality standards while narrowing participation.

Coverage Pathways: Medical vs. Pharmacy Benefit

One of the most consequential access variables is whether a specialty drug is covered under the medical or pharmacy benefit. This distinction affects patient cost-sharing, reimbursement, and operational workflow.

Medical Benefit and Buy-and-Bill

Provider-administered therapies, including infusions or injections delivered in clinical settings, are typically covered under the medical benefit through a traditional buy-and-bill model.

Under this approach:

• Providers purchase and administer the drug
• Providers bill for both the medication and its administration
• Patients pay cost-sharing under medical benefits

This model generally offers lower patient out-of-pocket costs and greater provider control. However, it requires providers to assume purchasing risk and navigate utilization management requirements.

Pharmacy Benefit and Buy-and-Bill

To manage costs, some payors shift provider-administered drugs to the pharmacy benefit through white bagging.

In this model:

• An insurer-designated specialty pharmacy dispenses the drug
• Medication is shipped to the provider
• The pharmacy bills the pharmacy benefit, while the provider bills for administration only

While this reduces payor risk, it often increases logistical complexity, fragments billing, and reduces provider revenue. In some cases, it can disrupt continuity of care.

Pharmacy Benefit Coverage

Self-administered specialty medications are typically covered under the pharmacy benefit.

In this model:

• Specialty pharmacies dispense medication directly to patients
• Claims are processed through the pharmacy benefit
• Patients pay a pharmacy-specific deductible, copayment, or coinsurance

Although manufacturer copay assistance can reduce point-of-sale costs, PBM-controlled formularies, rebate-driven tiering, copay accumulators, and post-sale claim adjustments often make coverage and reimbursement unpredictable.

The Role of 340B in Access

The 340B Drug Pricing Program supports underserved and rural populations by requiring manufacturers to provide discounted drugs to eligible providers. These savings help fund medication assistance, chronic disease management, mental health services, and care coordination programs.

Recent regulatory and operational shifts, including rebate-based pricing models, have increased complexity and compliance, as well as billing requirements such as 340B modifiers. For specialty pharmacies operating within 340B environments, strategic program management has become essential to sustaining access while meeting regulatory expectations.

Looking Ahead: Specialty Pharmacy Growth Trends and Sustainability

Specialty medications now account for more than half of total drug spending, reshaping access, reimbursement, and care delivery. As manufacturers bring increasingly complex and costly therapies to market, payors continue to refine utilization controls.

As a result, specialty pharmacies are being asked to support the full therapy lifecycle, from onboarding and adherence to outcome measurement, while navigating reimbursement models that strain traditional payment frameworks.

Long-term sustainability will depend on deeper clinical integration, stronger operational infrastructure, and the ability to demonstrate value beyond dispensing alone. Specialty pharmacies that successfully blend patient-centered care with operational sophistication will be best positioned to navigate the complexity ahead.

Find out how the right technology can help your specialty pharmacy successfully navigate the complexity of medical benefit billing and grow revenue. Learn more.